Navigation Links
Sinovac Biotech Holds Annual General Meeting
Date:4/10/2008

BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for March 25, 2008 was held two weeks later, on April 8, 2008.

During the April 8, 2008 Annual General Meeting, held at Sinovac's headquarters located at No. 39, Shangdi Xi Rd., Haidian District, Beijing, PRC, resolutions for the re-election of directors were passed, the Company's 2006 Annual Report was reviewed, and the appointment of Ernst & Young as Sinovac's registered public accountants was approved.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM)(H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccin and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington/Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic virus products for cancer, together ... enrollment has been initiated and the first patient ... trial called TRAVERSE.  The trial is evaluating the ...
... BRISBANE, Calif., Nov. 3, 2011 InterMune, Inc. (NASDAQ: ... for the third quarter and nine months ended September ... clinical development activities, including the launch of Esbriet® (pirfenidone) ... Executive Officer and President of InterMune said, "The third ...
... 3, 2011 Reportlinker.com announces that a new ... Global Biochip Markets: Microarrays ... INTRODUCTION  ... BCC,s goal for this study was to determine ...
Cached Biology Technology:Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 3Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 4Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 5Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... BIRMINGHAM, Ala. The U.S. Department of Energy (DOE) ... of Alabama at Birmingham (UAB) School of Engineering on ... the capture and permanent safe storage, or sequestration, of ... Southern Company, the parent company of Alabama Power. ...
... is publishing a special issue "Beyond the Origin: Charles ... of Species which was published 150 years ago in November ... Dr. Ulrich Kutschera, professor of plant physiology and evolutionary biology ... this special issue are available free of charge until 30 ...
... brilliance of butterfly wings has inspired a 3.2m, three-year ... fields of security, energy and the environment. The University ... signed a collaborative contract to develop new technologies based ... next three years a team of physicists from the ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: